返回 
加入收藏
胰岛素集中带量采购后我院胰岛素类药品的使用情况分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 胰岛素集中带量采购后我院胰岛素类药品的使用情况分析 |
| TITLE： | Analysis of the use of insulin products in our hospital after centralized volume-based procurement |
| 摘要： | 目的 分析胰岛素集中带量采购（以下简称“集采”）政策在我院的实施情况及对临床使用胰岛素类药品的影响。方法收集我院集采前（2021年7月4日－2022年1月3日）与集采后（2022年7月4日－2023年1月3日）胰岛素类药品的厂家、规格、使用量、销售金额及协议采购量等信息，采用限定日剂量（DDD）法计算用药频度（DDDs）、日均费用（DDC）、集采完成进度及实际节省费用。结果集采后，我院胰岛素类药品由集采前的20个增加至29个，除我院原胰岛素目录中的德谷门冬双胰岛素注射液未被集采外，其余已有品种均被集采。集采前后均以诺和诺德（中国）制药有限公司的门冬胰岛素30注射液使用量最大且DDDs排名第一；甘李药业股份有限公司和通化东宝药业股份有限公司的甘精胰岛素注射液因使用量显著增加而致销售金额增长；我院原胰岛素目录中，诺和诺德（中国）制药有限公司的德谷胰岛素注射液等集采完成进度较高，但新进品种的集采完成进度较低。集采后，我院实际节省费用共计1388582.66元。结论集采后，我院胰岛素类药品的选择和使用较合理，节省了患者胰岛素类药品的治疗费用，减轻了患者和社会的经济压力。 |
| ABSTRACT： | OBJECTIVE To analyze the implementation of insulin centralized volume-based procurement policy （hereinafter referred to as “centralized procurement”） in our hospital and its effect on the use of insulin products in clinical. METHODS The manufacturer， specifications， usage， sales amount and agreed purchase volume of insulin products in our hospital before （July 4， 2021 to January 3， 2022） and after （July 4， 2022 to January 3， 2023） the centralized procurement were collected. The defined daily dose （DDD） method was used to calculate defined daily doses （DDDs）， defined daily cost （DDC）， the progress of procurement completion and actual cost saving. RESULTS After the centralized procurement， the number of insulin products had increased from 20 to 29 in our hospital； except for the Insulin degludec/aspart injection in our hospital’s original insulin catalog that had not been centrally purchased， all other existing varieties had been included in centralized procurement catalog. The use of Insulin aspart 30 injection produced by Novo Nordisk （China） Pharmaceutical Co.， Ltd. always ranked the first place in the list of usage and DDDs before and after the centralized procurement. The sales amount of Insulin glargine injection produced by Ganli Pharmaceutical Co.， Ltd. and Tonghua Dongbao Pharmaceutical Co.， Ltd. increased significantly due to the significant increase in usage. The centralized procurement of Degu insulin injection from Novo Nordisk （China） Pharmaceutical Co.， Ltd. had achieved a relatively high completion rate in our hospital’s original insulin catalog， while the completion rate for new varieties was low. After the centralized procurement， our hospital actually saved a total of 1 388 582.66 yuan in expenses. CONCLUSIONS After the centralized procurement， the selection and usage of insulin varieties in our hospital are reasonable， which saves patients’ insulin treatment costs， and reduces economic pressure on patients and society. |
| 期刊： | 2023年第34卷第18期 |
| 作者： | 董雅芬；邱彦；金辉；刘艳平；王建 |
| AUTHORS： | DONG Yafen，QIU Yan，JIN Hui，LIU Yanping，WANG Jian |
| 关键字： | 胰岛素；集中带量采购；用药频度；日均费用；实际节省费用 |
| KEYWORDS： | insulin； centralized volume-based procurement； defined daily doses； defined daily cost； actual cost saving |
| 阅读数： | 103 次 |
| 本月下载数： | 16 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
